[{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS PBC Announces Positive Results from Confirmatory Phase 3 \"MAPP2\" Trial of MDMA-Assisted Therapy for Treatment of PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Helena","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Lykos Therapeutics
MDMA (Midomafetamine) is a ring-substituted amphetamine analog with reinforcing psychoactive effects. It is a 5-HT2A receptor agonist, which is under development for the treatment of posttraumatic stress disorder.
The proceeds will support regulatory and pre-launch activities for investigational MDMA-assisted therapy, an investigational modality being studied using a combination of MDMA, psychological intervention and other supportive services for post-traumatic stress disorder.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline being developed the treatment of for PTSD.
MDMA (3,4-methylenedioxymethamphetamine) is a 5-HT2A receptor agonist, small molecule drug candidate, which is currently being evaluated for the treatment of patients with Post-traumatic stress disorder.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline.